DE602006012328D1 - Bifunktionelle proteinanker - Google Patents

Bifunktionelle proteinanker

Info

Publication number
DE602006012328D1
DE602006012328D1 DE602006012328T DE602006012328T DE602006012328D1 DE 602006012328 D1 DE602006012328 D1 DE 602006012328D1 DE 602006012328 T DE602006012328 T DE 602006012328T DE 602006012328 T DE602006012328 T DE 602006012328T DE 602006012328 D1 DE602006012328 D1 DE 602006012328D1
Authority
DE
Germany
Prior art keywords
antigen
immunogenic carrier
polypeptide
interest
bifunctional protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006012328T
Other languages
English (en)
Inventor
Cornelis Johannes Leenhouts
Rosmalen Maarten Leonardus Van
Tjibbe Bosma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Nanosystems BV
Original Assignee
Applied Nanosystems BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Nanosystems BV filed Critical Applied Nanosystems BV
Publication of DE602006012328D1 publication Critical patent/DE602006012328D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602006012328T 2005-07-20 2006-07-20 Bifunktionelle proteinanker Active DE602006012328D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05076680A EP1746103A1 (de) 2005-07-20 2005-07-20 Bifunktionelle Protein-Anker
PCT/NL2006/000382 WO2007011216A2 (en) 2005-07-20 2006-07-20 Bifunctional protein anchors

Publications (1)

Publication Number Publication Date
DE602006012328D1 true DE602006012328D1 (de) 2010-04-01

Family

ID=35005648

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006012328T Active DE602006012328D1 (de) 2005-07-20 2006-07-20 Bifunktionelle proteinanker

Country Status (10)

Country Link
US (3) US9011870B2 (de)
EP (2) EP1746103A1 (de)
CN (1) CN101268095B (de)
AT (1) ATE457999T1 (de)
AU (1) AU2006270565B2 (de)
CA (1) CA2615738C (de)
DE (1) DE602006012328D1 (de)
DK (1) DK1910408T3 (de)
NZ (1) NZ565271A (de)
WO (1) WO2007011216A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746103A1 (de) * 2005-07-20 2007-01-24 Applied NanoSystems B.V. Bifunktionelle Protein-Anker
EP2168987A1 (de) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunktionelles Linker-Protein enthaltend einen anti-Hämagglutinin-Antikörper, ein konserviertes Influenza-Antigen und eine immunostimulierende Träger-Bindungsdomäne
US20130004547A1 (en) * 2009-07-13 2013-01-03 Vaxgene Corporation Oral vaccines produced and administered using edible micro-organisms including lactic acid bacterial strains
EP2308506A1 (de) 2009-10-02 2011-04-13 Mucosis B.V. Intranasale Adjuvansimpfstoffformulierungen
CN102648003B (zh) * 2009-10-09 2016-01-13 儿童医疗中心有限公司 选择性裂解的全细胞疫苗
CN102796756A (zh) * 2012-06-28 2012-11-28 郑州大学 可在乳酸乳球菌表面展示表达异源基因的载体及其制备方法与应用
CN102796757A (zh) * 2012-06-28 2012-11-28 郑州大学 在乳酸乳球菌表面展示表达幽门螺杆菌蛋白的载体及其制备方法和应用
CN107417773B (zh) * 2016-05-30 2020-09-08 国盛生化股份有限公司 黏合细胞壁之胜肽
CN107033224B (zh) * 2017-01-26 2018-11-02 江苏省农业科学院 一种口蹄疫病毒灭活抗原纯化浓缩方法
CN106589077B (zh) * 2017-01-26 2020-07-10 江苏省农业科学院 一种猪圆环病毒2型抗原纯化浓缩方法
CN107899017B (zh) * 2017-08-16 2021-06-08 祝康生物科技有限公司 一种天然生物纳米靶向药物复合体材料及其制备方法和应用
CN107460173B (zh) * 2017-09-08 2020-09-22 江苏省农业科学院 一种纯化猪流行性腹泻病毒、猪繁殖与呼吸综合征病毒或禽流感病毒的方法
CN109180818A (zh) * 2018-08-08 2019-01-11 天津大学 一种利用gem纯化包涵体的方法
CN109022395A (zh) * 2018-08-08 2018-12-18 天津大学 一种纯化固定化重组α-淀粉酶的方法
CN110628746A (zh) * 2019-09-10 2019-12-31 天津大学 制备BEM用于纯化固定化带有AcmA重组蛋白的方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151350A (en) 1982-10-27 1992-09-29 Repligen Corporation Cloned genes encoding recombinant protein a
ZA94916B (en) * 1993-02-10 1995-08-10 Unilever Plc Immobilized proteins with specific binding capacities and their use in processes and products
EP0916726A1 (de) * 1997-11-13 1999-05-19 Rijksuniversiteit te Groningen Befestigungs-Substanzen an Mikroorganismen
ES2343304T3 (es) * 1999-06-25 2010-07-28 Wyeth Holdings Corporation Produccion de la forma lipidada de las lipoproteinas asociadas a peptidoglicano de bacterias gram-negativas.
AU2001280836A1 (en) 2000-07-31 2002-02-13 Meditech Pharmaceuticals, Inc. Compounds, compositions, and methods for the treatment of plant bacterial and fungal infections
JP4651213B2 (ja) 2001-03-27 2011-03-16 株式会社グライコメディクス インフルエンザウイルス・ヘマグルチニン結合性ペプチド
DE60232071D1 (de) * 2001-06-11 2009-06-04 Applied Nanosystems Bv Verfahren zur bindung von acma-typ protein anker fusionen an mikroorganismen zellwandmaterialien
EP1477802A1 (de) 2003-05-16 2004-11-17 Erasmus Universiteit Rotterdam Verfahren zur Auswahl und zum Herstellung von Impfstoffkomponenten, und deren Verwendung in Impfstoffen
CA2529001A1 (en) 2003-06-10 2004-12-16 Catchmabs B.V. Binding peptides: methods for their generation and use
EP1746103A1 (de) * 2005-07-20 2007-01-24 Applied NanoSystems B.V. Bifunktionelle Protein-Anker
EP2168987A1 (de) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunktionelles Linker-Protein enthaltend einen anti-Hämagglutinin-Antikörper, ein konserviertes Influenza-Antigen und eine immunostimulierende Träger-Bindungsdomäne
EP2308506A1 (de) * 2009-10-02 2011-04-13 Mucosis B.V. Intranasale Adjuvansimpfstoffformulierungen
DK2689016T3 (en) * 2011-03-22 2015-04-27 Mucosis Bv Immunogenic formations in particle form and fremgangmsåder for the production thereof

Also Published As

Publication number Publication date
WO2007011216A3 (en) 2007-03-08
AU2006270565B2 (en) 2011-05-12
EP1746103A1 (de) 2007-01-24
US20150196659A1 (en) 2015-07-16
CN101268095A (zh) 2008-09-17
EP1910408A2 (de) 2008-04-16
US20160136294A1 (en) 2016-05-19
CA2615738C (en) 2013-06-04
DK1910408T3 (da) 2010-06-07
US20090263414A1 (en) 2009-10-22
AU2006270565A1 (en) 2007-01-25
CA2615738A1 (en) 2007-01-25
US9011870B2 (en) 2015-04-21
CN101268095B (zh) 2013-01-09
EP1910408B1 (de) 2010-02-17
WO2007011216A2 (en) 2007-01-25
ATE457999T1 (de) 2010-03-15
NZ565271A (en) 2010-07-30

Similar Documents

Publication Publication Date Title
DE602006012328D1 (de) Bifunktionelle proteinanker
HRP20201770T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
WO2002080851A3 (en) Chimeric vaccines
CY1107390T1 (el) Εμβολιο εναντι αντιγονων απο βακτηριδια
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
WO2007067681A3 (en) Immunostimulatory compositions and methods
WO2008040362A3 (en) Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
WO2004075829A3 (en) Adjuvanted influenza vaccine
TR200103333T2 (tr) Dayanıklığı ve biyolojik uygunluğu iyileştiren yardımcı ilaç (SBA)
BRPI0411854A (pt) veìculos protéicos para vacinas
WO2006083301A3 (en) Immunogenic compositions comprising hmgb1 polypeptides
DK2142570T3 (da) Anti-EpCam-antistof og anvendelser deraf
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
WO2005105139A3 (en) Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
WO2006083792A3 (en) Novel polypeptide ligands for toll-like receptor 2 (tlr2)
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
WO2005007673A3 (en) Immunogenic peptides
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
WO2009070507A3 (en) Anaplasma phagocytophilum (aph) antigens and antibodies specific for anaplasma
WO2006117538A3 (en) Assays for diagnosis of tuberculosis and uses thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition